Form 4: BioAffinity Technologies Executive Acquires Shares Through Stock Grant

Timothy P. Zannes, Secretary, EVP, and General Counsel of bioAffinity Technologies, acquired 8,641 shares of common stock through a grant, increasing his holdings to 54,765 shares.

Summary

• Timothy P. Zannes, an executive at bioAffinity Technologies, acquired 8,641 shares of common stock on January 10, 2025.
• The acquisition was a grant, with the shares priced at $0.
• Following the transaction, Zannes's total holdings in bioAffinity Technologies amount to 54,765 shares.
• The restricted shares vest pro rata on a monthly basis over 12 months, starting February 10, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock acquisition by an executive. The grant itself could be seen as a positive, but the document is primarily informational.

Positives

• The acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC when company insiders trade in their company's stock. It provides transparency to the market regarding the actions of company executives.

Stakeholder Impact

• The acquisition of shares by an executive could have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

bioAffinity Technologies, BIAF, Timothy P. Zannes, stock grant, beneficial ownership, Form 4, SEC, shares, acquisition